Merrimack Pharmaceuticals sets new terms, now seeking $100 million

By Renaissance Capital,

Shutterstock photo

Merrimack Pharmaceuticals, which postponed its IPO in February, announced new terms on Monday. The Cambridge, MA-based company now plans to raise $100 million (down from $150 million) by offering 14.3 million shares at a price of $7.00. At the $7 price, Merrimack Pharmaceuticals will command a market value of $647 million (down from $853 million). Merrimack Pharmaceuticals, which uses its Network Biology system to discover and develop cancer treatments, plans to list on the NASDAQ under the symbol MACK. J.P. Morgan is the bookrunner on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing IPOs
Referenced Stocks: MACK

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by